Nicholas I Paton
Overview
Explore the profile of Nicholas I Paton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3093
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cross G, Sari I, Burkill S, Yap C, Nguyen H, Quyet D, et al.
Nat Commun
. 2024 Dec;
15(1):10475.
PMID: 39622823
Adjunctive rosuvastatin for rifampicin-susceptible pulmonary tuberculosis (rs-PTB) shows no effect on microbiological or radiological outcomes in a phase IIb randomised, controlled trial (NCT04504851). We explore the impact of adjunctive rosuvastatin...
2.
Lienhardt C, Dooley K, Nahid P, Wells C, Ryckman T, Kendall E, et al.
Bull World Health Organ
. 2024 Jul;
102(8):600-607.
PMID: 39070602
Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with tuberculosis are desperately needed. In 2016, the World Health Organization (WHO) developed target...
3.
Kityo C, Mambule I, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, et al.
Lancet Infect Dis
. 2024 May;
24(10):1083-1092.
PMID: 38821073
Background: Long-acting injectable cabotegravir and rilpivirine is licensed for individualised treatment of HIV-1 infection in resource-rich settings. Additional evidence is required to support use in African treatment programmes where demographic...
4.
Paton N, Gurumurthy M, Lu Q, Leek F, Kwan P, Koh H, et al.
J Infect Dis
. 2024 Mar;
230(3):590-597.
PMID: 38527849
Background: Interleukin 4 (IL-4), increased in tuberculosis infection, may impair bacterial killing. Blocking IL-4 confers benefit in animal models. We evaluated safety and efficacy of pascolizumab (humanized anti-IL-4 monoclonal antibody)...
5.
Paton N, Stohr W, Arenas-Pinto A, Clarke A, Williams I, Johnson M, et al.
EClinicalMedicine
. 2024 Feb;
69:102457.
PMID: 38361989
Background: Treatment-simplification strategies are important tools for patient-centred management. We evaluated long-term outcomes from a PI monotherapy switch strategy. Methods: Eligible participants attending 43 UK treatment centres had a viral...
6.
Schuldt A, Bern H, Hart M, Gompels M, Winston A, Clarke A, et al.
Viruses
. 2024 Jan;
16(1).
PMID: 38275937
The aim of this study is to identify the factors associated with peripheral neuropathy and to explore neurofilament light chain (NfL) as a biomarker for peripheral neuropathy (PN) in effectively...
7.
Cross G, O Doherty J, Chang C, Kelleher A, Paton N
J Infect Dis
. 2023 Oct;
229(4):1229-1238.
PMID: 37788578
Positron emission tomography-computed tomography (PET-CT) has the potential to revolutionize research in infectious diseases, as it has done with cancer. There is growing interest in it as a biomarker in...
8.
Motta I, Boeree M, Chesov D, Dheda K, Gunther G, Horsburgh Jr C, et al.
Clin Microbiol Infect
. 2023 Jul;
30(9):1107-1114.
PMID: 37482332
Background: Tuberculosis (TB) is a global health challenge and one of the leading causes of death worldwide. In the last decade, the TB treatment landscape has dramatically changed. After long...
9.
Paton N, Cousins C, Suresh C
N Engl J Med
. 2023 Jun;
388(24):2298.
PMID: 37314717
No abstract available.
10.
Cross G, Sari I, Kityo C, Lu Q, Pokharkar Y, Moorakonda R, et al.
Lancet Infect Dis
. 2023 Mar;
23(7):847-855.
PMID: 36966799
Background: Shorter treatments are needed for drug-susceptible tuberculosis. Adjunctive statins increase bactericidal activity in preclinical tuberculosis models. We investigated the safety and efficacy of adjunctive rosuvastatin in people with tuberculosis....